|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||28.70 - 28.88|
|52 Week Range||28.48 - 36.82|
|PE Ratio (TTM)||21.71|
|Forward Dividend & Yield||1.11 (3.82%)|
|1y Target Est||N/A|
The chief U.S. economist at Standard & Poor’s says reductions in workplace gender inequalities could actually help the economy grow by 5-10% over the next few decades. Yahoo Finance’s Alexis Christoforous, Dan Roberts and Julia La Roche discuss.
The gravy train … is empty. At least for some KFC restaurants in the UK. Yahoo Finance’s Alexis Christoforous, Andy Serwer, and Julia La Roche discuss the chicken chain’s latest problem.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.
In 4Q17, Merck’s (MRK) Emend generated revenues of $143 million, which reflected a ~1% decline on a YoY (year-over-year) basis but a 4% rise on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Emend reported revenues of $85 million and $58 million, respectively, compared with $90 million and $53 million in 4Q16, which reflected a ~6% decline and an 8% rise, respectively, YoY. In fiscal 2017, Emend generated revenues of $556 million, compared with $549 million in 2016, which reflected a ~1% rise YoY.
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.
Swiss drugmaker Roche (ROG.S) said it will put a cancer specialist at the helm of its Swiss-based research efforts in April, after the scientist who led the unit for five years resigned for personal reasons. The biggest maker of cancer drugs named William Pao to lead its 2,200-employee Pharma Research and Early Development (pRED) unit on Thursday. Current postholder Reed, 59, arrived in Basel in 2013 to rebuild Roche's Swiss research after restructuring.
In the diabetes care segment, the company is currently focused on developing insulin and glucagon-like peptide 1 (or GLP-1) products, which demonstrate distinct clinical advantages in terms of factors such as the absence of hypoglycemia, reduced comorbidity risk related to cardiovascular events, and weight loss. Novo Nordisk is also evaluating new treatment options with improved delivery mechanisms, such as oral delivery. The above diagram shows the evolution of Novo Nordisk’s insulin and GLP-1 franchises since 1923 and 1986, respectively.
Glaxo (GSK) presents data from OSMO study on a new respiratory medicine, Nucala, and on INSPIRING, a phase IIIb study on investigational HIV candidate dolutegravir at medical conferences.
Moody's Investors Service says that Yestar Healthcare Holdings Company Limited's announcement of an expected improvement in its consolidated net profit in 2017 supports its Ba3 corporate family rating ...
Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world. Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs - something Roche aims to leverage, for example, with last month's $2 billion purchase of Flatiron Health. Real-world evidence involves collecting data outside traditional randomised clinical trials, the current gold standard for judging medicines, and interest in the field is ballooning.
Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world. Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs - something Roche (ROG.S) aims to leverage, for example, with last month's $2 billion purchase of Flatiron Health. Real-world evidence involves collecting data outside traditional randomized clinical trials, the current gold standard for judging medicines, and interest in the field is ballooning.
We expect Immune Design (IMDZ) to shed light on the progression of the trails on pipeline candidates when it releases fourth-quarter earnings results on Mar 6.
Novartis: What Are the Major Growth Drivers for 2018? On August 30, 2017, Novartis’ (NVS) CAR T-cell therapy, Kymriah, secured approval from the FDA as a treatment option for patients below 25 years of age who have B-cell precursor acute lymphoblastic leukemia (or ALL). This drug, which is developed by the company in collaboration with the University of Pennsylvania, is indicated only in cases when ALL is refractory or has relapsed a second time or more.